Ad
related to: rituximab information for patientsvyvgarthcp.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Rituximab, a drug that depletes B cells, is the first line agent for patients with HHV-8-associated MCD and is recommended in all patients with proven HHV-8-associated MCD unless they have a contraindication to the medication or have failed treatment with the medication in the past.
etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin plus rituximab: B cell Non-Hodgkin lymphomas: ESHAP: etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent: Non-Hodgkin lymphoma: ESHAP-R or R-ESHAP: etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C ...
FCM, or FMC in the context of chemotherapy is an acronym for a chemotherapy regimen that is used in the treatment of indolent B cell non-Hodgkin's lymphomas.In combination with Rituximab, this regimen is called R-FCM or R-FMC, or FCM-R, FMC-R.
This regimen also does not contain vincristine and can be used in patients with neuropathy. There are several modifications of CEPP. In combination with bleomycin, this regimen is called CEPP (B). [2] With the further addition of the anti-CD20 monoclonal antibody rituximab, it is called R-CEPP(B). R-CEPP(B) regimen consists of:
This regimen can also be combined with the monoclonal antibody rituximab if the lymphoma is of B cell origin; this combination is called R-CHOP. In 2002, a randomized controlled trial showed a higher complete response rate for R-CHOP vs CHOP in elderly patients with Diffuse Large-B-Cell Lymphoma (76% vs 63%). [4]
GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin's lymphoma and Hodgkin's lymphoma.. When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R.
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.
Ad
related to: rituximab information for patientsvyvgarthcp.com has been visited by 10K+ users in the past month